TENX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tenax Therapeutics Inc (TENX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has weak financial performance, and no proprietary trading signals are present. While there is a positive analyst rating and price target increase, the technical indicators and lack of recent news or trading trends suggest that the current entry point is not optimal.
The MACD histogram is negative and expanding (-0.124), indicating bearish momentum. RSI is at 34.834, which is neutral but nearing oversold territory. Moving averages are converging, showing no clear trend. The pre-market price of $11.748 is close to the S1 support level ($11.646), suggesting limited downside but no strong upward momentum.
Guggenheim raised the price target to $25 from $14 and reiterated a Buy rating, citing the upcoming pivotal readout for oral levosimendan in 2026.
Technical indicators show bearish momentum.
For Q3 2025, revenue remained at $0 with no growth. Net income improved YoY but remains negative at -$15.8M. EPS improved to -0.4, up 110.53% YoY, but still negative. Gross margin is 0, showing no profitability.
Guggenheim reiterated a Buy rating and increased the price target to $25, citing the company's upcoming pivotal readout for oral levosimendan in 2026. No other analyst updates are available.
